Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Queensland Health
QuintilesIMS
Healthtrust
Mallinckrodt
Julphar

Generated: August 21, 2019

DrugPatentWatch Database Preview

Claims for Patent: 7,067,475

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,067,475
Title:Tek antagonists
Abstract: The present invention provides Tek antagonists and methods of inhibiting angiogenesis in a mammal by administering Tek antagonists. The methods are particularly useful in treating diseases or conditions mediated by angiogenesis, such as solid tumors and diseases or conditions characterized by ocular neovascularization.
Inventor(s): Cerretti; Douglas P. (Seattle, WA), Borges; Luis G. (Seattle, WA), Fanslow, III; William C. (Seattle, WA)
Assignee: Immunex Corporation (Seattle, WA)
Application Number:10/357,653
Patent Claims:1. A method of inhibiting angiogenesis in a mammal in need of such treatment, comprising administering to the mammal an inhibition-effective amount of a polypeptide comprising a fragment of Tek extracellular domain, shown as residues 19 745 of SEQ ID NO:1, wherein the polypeptide lacks residues 473 745 of SEQ ID NO:1 containing fibronectin type III (FN III) motifs and wherein the polypeptide has a higher binding affinity for angiopoietin-1 or angiopoietin-2 or angiopoietin-4 than does a polypeptide comprising the full length Tek extracellular domain.

2. A method as claimed in claim 1, wherein said polypeptide is a multimer.

3. The method of claim 2 wherein the multimer is a dimer or trimer.

4. The method of claim 2 wherein said multimer comprises an Fc polypeptide or a leucine zipper.

5. The method of one of claims 2 4 wherein the Tek is human Tek.

6. The method of claim 5 wherein the Tek multimer comprises a polypeptide having a sequence selected from the group consisting of residues 23 704 of SEQ ID NO:2, and residues 23 472 of SEQ ID NO:2.

7. The method of one of claims 2 4 wherein the Tek multimer comprises a polypeptide having a sequence selected from the group consisting of residues 23 704 of SEQ ID NO:2, and residues 23 472 of SEQ ID NO:2.

8. A method of inhibiting angiogenesis in a mammal in need of such treatment, comprising administering to the mammal an inhibition-effective amount of a compound selected from the group consisting of: (a) a polypeptide comprising a fragment of Tek extracellular domain, shown as residues 19 745 of SEQ ID NO:1, wherein the polypeptide lacks residues 473 745 of SEQ ID NO:1 containing fibronectin type III (FN III) motifs and wherein the polypeptide has a higher binding affinity for angiopoietin-1 or angiopoietin-2 or angiopoietin-4 than does a polypeptide comprising the full length Tek extracellular domain; and (b) a multimer of the polypeptide described in (a).

9. The method of claim 8 wherein the mammal has a disease or condition mediated by angiogenesis.

10. The method of claim 9 wherein the disease or condition is characterized by ocular neovascularization.

11. The method of claim 9 wherein the disease or condition is a solid tumor.

12. The method of claim 8 wherein the method further comprises treating the mammal with a second chemotherapeutic agent.

13. The method of claim 12 wherein the second chemotherapeutic agent is selected from the group consisting of alkylating agents, antimetabolites, vinca alkaloids and other plant-derived chemotherapeutics, nitrosoureas, antitumor antibiotics, antitumor enzymes, topoisomerase inhibitors, platinum analogs, adrenocortical suppressants, hormones, hormone agonists, hormone antagonists, antibodies, immunotherapeutics, blood cell factors, radiotherapeutics, and biological response modifiers.

14. The method of claim 12 wherein the second chemotherapeutic agent is selected from the group consisting of cisplatin, cyclophosphamide, mechloretamine, melphalan, bleomycin, carboplatin, fluorouracil, 5-fluorodeoxyuridine, methotrexate, taxol, asparaginase, vincristine, and vinblastine, lymphokines and cytokines such as interleukins, interferons (including alpha., beta, or delta), and TNF, chlorambucil, busulfan, carmustine, lomustine, semustine, streptozocin, dacarbazine, cytarabine, mercaptopurine, thioguanine, vindesine, etoposide, teniposide, dactinomycin, daunorubicin, doxorubicin, bleomycin, plicamycin, mitomycin, L-asparaginase, hydroxyurea, methylhydrazine, mitotane, tamoxifen, and fluoxymesterone.

15. The method of claim 12 wherein the second chemotherapeutic agent is selected from the group consisting of Flt3 ligand, CD40 ligand, interleukin-2, interleukin-12, 4-1 BB ligand, anti-4-1 BB antibodies, TNF antagonists and TNF receptor antagonists including TNFR/Fc, TWEAK antagonists and TWEAK-R antagonists including TWEAK-R/Fc, TRAIL, CD148 agonists, VEGF antagonists including anti-VEGF antibodies, and VEGF receptor antagonists.

16. The method of claim 8 wherein the method further comprises treating the mammal with radiation.

17. A method of inhibiting the binding of a Tek ligand to Tek in a mammal in need of such treatment, comprising administering to the mammal an inhibition-effective amount of compound selected from the group consisting of: (a) a polypeptide comprising a fragment of Tek extracellular domain, shown as residues 19 745 of SEQ ID NO:1, wherein the polypeptide lacks residues 473 745 of SEQ ID NO:1 containing fibronectin type III (FN III) motifs and wherein the polypeptide has a higher binding affinity for angiopoietin-1 or angiopoietin-2 or angiopoietin-4 than does a polypeptide comprising the full length Tek extracellular domain; and (b) a multimer of the polypeptide described in (a).

Details for Patent 7,067,475

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Merck ELSPAR asparaginase VIAL 101063 001 1978-01-10   Try a Free Trial Immunex Corporation (Seattle, WA) 2020-06-07 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Chubb
Johnson and Johnson
Moodys
Covington
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.